MALDI-TOF MS profiling as the first-tier screen for sickle cell disease in neonates: Matching throughput to objectives

Proteomics - Clinical Applications

Volumn 5, Issue 7-8, 2011, Pages 405-414

  Hachani, Johan ^a,b,c   Duban Deweer, Sophie ^a,b,c   Pottiez, Gwënaël ^a,b,c   Renom, Gilles ^d   Flahaut, Christophe ^a,b,c   Périni, Jean Marc ^a,d,e  

^a UNIV LILLE   (France)

^b LBHE   (France)

^c IMPRT IFR114   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e AFDPHE   (France)

Author keywords

MS; Neonatal screening; Sickle cell disease; Thalassaemia

Indexed keywords

HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN GAMMA CHAIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FETUS HYDROPS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; ISOELECTRIC FOCUSING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SICKLE CELL ANEMIA; THALASSEMIA;

ANEMIA, SICKLE CELL; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEMOGLOBIN, SICKLE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFANT, NEWBORN; MALE; NEONATAL SCREENING; PUBLIC HEALTH; QUALITY CONTROL; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 79960881984     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000093     Document Type: Article

References (22)

1. Benkerrou, M., Le dépistage néonatal ciblé de la drépanocytose en France métropolitaine: raisons et résultats. Mt Pédiatrie 2002, 5, 159-163.
2. Ackermann, B. L., Hale, J. E., Duffin, K. L., The role of mass spectrometry in biomarker discovery and measurement. Curr. Drug Metab. 2006, 7, 525-539.
3. Franck, J., Arafah, K., Elayed, M., Bonnel, D. et al., MALDI imaging mass spectrometry: state of the art technology in clinical proteomics. Mol. Cell. Proteomics 2009, 8, 2023-2033.
4. Krishnamurthy, T., Ross, P. L., Rapid identification of bacteria by direct matrix-assisted laser desorption/ionization mass spectrometric analysis of whole cells. Rapid Commun. Mass Spectrom. 1996, 10, 1992-1996.
5. Pennanec, X., Dufour, A., Haras, D., Rehel, K., A quick and easy method to identify bacteria by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24, 384-392.
6. Kiernan, U. A., Black, J. A., Williams, P., Nelson, R. W., High-throughput analysis of hemoglobin from neonates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2002, 48, 947-949.
7. Rai, D. K., Griffiths, W. J., Landin, B., Wild, B. J. et al., Accurate mass measurement by electrospray ionization quadrupole mass spectrometry: detection of variants differing by<6Da from normal in human hemoglobin heterozygotes. Anal. Chem. 2003, 75, 1978-1982.
8. Wild, B. J., Green, B. N., Cooper, E. K., Lalloz, M. R. et al., Rapid identification of hemoglobin variants by electrospray ionization mass spectrometry. Blood Cells Mol. Dis. 2001, 27, 691-704.
9. Wild, B. J., Green, B. N., Stephens, A. D., The potential of electrospray ionization mass spectrometry for the diagnosis of hemoglobin variants found in newborn screening. Blood Cells Mol. Dis. 2004, 33, 308-317.
10. Daniel, Y. A., Turner, C., Haynes, R. M., Hunt, B. J., Dalton, R. N., Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry-mass spectrometry. Br. J. Haematol. 2005, 130, 635-643.
11. Boemer, F., Ketelslegers, O., Minon, J. M., Bours, V., Schoos, R., Newborn screening for sickle cell disease using tandem mass spectrometry. Clin. Chem. 2008, 54, 2036-2041.
12. Girosi, F., An equivalence between sparse approximation and support vector machines. Neural Comput. 1998, 10, 1455-1480.
13. Galacteros, F., Guilloud-Bataille, M., Feingold, J., Sex, gestational age, and weight dependancy of adult hemoglobin concentration in normal newborns. Blood 1991, 78, 1121-1124.
14. Bardakdjian-Michau, J., Bahuau, M., Hurtrel, D., Godart, C. et al., Neonatal screening for sickle cell disease in France. J. Clin. Pathol. 2009, 62, 31-33.
15. Giordano, P. C., Starting neonatal screening for haemoglobinopathies in The Netherlands. J. Clin. Pathol. 2009, 62, 18-21.
16. Gulbis, B., Ferster, A., Cotton, F., Lebouchard, M. P. et al., Neonatal haemoglobinopathy screening: review of a 10-year programme in Brussels. J. Med. Screen. 2006, 13, 76-78.
17. de Montalembert, M., Girot, R., Galacteros, F., Sickle cell disease in France in 2006: results and challenges. Arch. Pediatr. 2006, 13, 1191-1194.
18. Grosse, S. D., Olney, R. S., Baily, M. A., The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl. Health Econ. Health Pol. 2005, 4, 239-247.
19. Harris, M. S., Eckman, J. R., Georgia's experience with newborn screening: 1981 to 1985. Pediatrics 1989, 83, 858-860.
20. Sparbier, K., Wenzel, T., Dihazi, H., Blaschke, S. et al., Immuno-MALDI-TOF MS: new perspectives for clinical applications of mass spectrometry. Proteomics 2009, 9, 1442-1450.
21. Jiang, J., Parker, C. E., Hoadley, K. A., Perou, C. M. et al., Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics Clin. Appl. 2007, 1, 1651-1659.
22. Reid, J. D., Holmes, D. T., Mason, D. R., Shah, B., Borchers, C. H., Towards the development of an immuno MALDI (iMALDI) mass spectrometry assay for the diagnosis of hypertension. J. Am. Soc. Mass Spectrom. 2010, 21, 1680-1686.